Financials EQUINOX NEPREMICNINE d.d.
Equities
EQNX
SI0031117813
Real Estate Development & Operations
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
54 EUR | 0.00% | 0.00% | +2.86% |
2022 | An unknown buyer acquired an unknown minority stake in EQUINOX NEPREMICNINE d.d. from Axor holding d.d. | CI |
2022 | EQUINOX NEPREMICNINE d.d. has completed an IPO. | CI |
Valuation
Fiscal Period: December | 2022 | 2023 |
---|---|---|
Capitalization 1 | 89.69 | 94.18 |
Enterprise Value (EV) 1 | 93.48 | 99.41 |
P/E ratio | 126 x | 108 x |
Yield | - | - |
Capitalization / Revenue | 12.2 x | 12.1 x |
EV / Revenue | 12.7 x | 12.8 x |
EV / EBITDA | 19.4 x | 24.1 x |
EV / FCF | 26,119,612 x | 28,906,088 x |
FCF Yield | 0% | 0% |
Price to Book | 2.17 x | 2.36 x |
Nbr of stocks (in thousands) | 1,794 | 1,794 |
Reference price 2 | 50.00 | 52.50 |
Announcement Date | 13/02/24 | 13/02/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Net sales 1 | 6.715 | 7.344 | 7.787 |
EBITDA 1 | 3.956 | 4.813 | 4.131 |
EBIT 1 | 0.5221 | 1.404 | 0.3673 |
Operating Margin | 7.78% | 19.11% | 4.72% |
Earnings before Tax (EBT) 1 | 0.3836 | 0.8496 | 0.971 |
Net income 1 | 0.5399 | 0.712 | 0.8691 |
Net margin | 8.04% | 9.69% | 11.16% |
EPS 2 | 0.3010 | 0.3969 | 0.4845 |
Free Cash Flow | - | 3.579 | 3.439 |
FCF margin | - | 48.73% | 44.16% |
FCF Conversion (EBITDA) | - | 74.36% | 83.26% |
FCF Conversion (Net income) | - | 502.67% | 395.7% |
Dividend per Share | - | - | - |
Announcement Date | 15/04/22 | 13/02/24 | 13/02/24 |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Net Debt 1 | 2.05 | 3.79 | 5.23 |
Net Cash position 1 | - | - | - |
Leverage (Debt/EBITDA) | 0.518 x | 0.787 x | 1.267 x |
Free Cash Flow | - | 3.58 | 3.44 |
ROE (net income / shareholders' equity) | - | 1.75% | 2.14% |
ROA (Net income/ Total Assets) | - | 1.52% | 0.41% |
Assets 1 | - | 46.69 | 214.5 |
Book Value Per Share 2 | 22.30 | 23.00 | 22.20 |
Cash Flow per Share 2 | 3.730 | 6.020 | 2.040 |
Capex 1 | 0.23 | 0.16 | - |
Capex / Sales | 3.5% | 2.2% | - |
Announcement Date | 15/04/22 | 13/02/24 | 13/02/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+2.86% | 104M | |
+10.00% | 28.66B | |
+27.88% | 26.77B | |
-7.82% | 25.83B | |
+15.53% | 24.86B | |
+45.81% | 22.8B | |
+9.88% | 21.41B | |
+1.01% | 19.61B | |
+27.40% | 16.36B | |
-10.20% | 15.93B |
- Stock Market
- Equities
- EQNX Stock
- Financials EQUINOX NEPREMICNINE d.d.